PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae163 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Arathi Mohan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Cholangiocarcinoma, Poly(ADP-ribose) Polymerase Inhibitors, Bile Duct Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Rogel Cancer Center, University of Michigan.
Abstract (Originalsprache)
Background
Isocitrate dehydrogenase 1 (IDH1) missense mutations occur at a frequency of 10%-15% in intrahepatic cholangiocarcinoma (iCCA). IDH1 mutations result in accumulation of (R)-2-hydroxyglutarate, an oncometabolite that leads to DNA hypermethylation and impairment of homologous recombination (HR). Impairment of HR results in a “BRCAness” phenotype which may confer sensitivity to poly(ADP ribose) polymerase (PARP) inhibition.
Methods
We conducted a retrospective cohort review to identify patients with advanced, IDH1 mutated iCCA treated with a PARP inhibitor (PARPi) at the University of Michigan between 2018 and 2023. Patients are described with respect to prior lines of therapy, response to platinum-based chemotherapy, and progression-free survival (PFS) and overall survival (OS) from the time of PARPi initiation.
Results
Between 2018 and 2023 we identified 40 patients with IDH1 mutated iCCA of which 6 patients were treated with a PARPi as monotherapy or in combination with an ATR inhibitor or anti-PD-1 immune checkpoint inhibitor. Majority of patients (n = 5) carried an IDH1 R132C mutation per tissue-based next generation sequencing. All patients had previously received at least one line of cisplatin-based systemic therapy for advanced disease prior to treatment with PARPi. PFS and OS from time of PARPi initiation ranged from 1.4 to 18.5 months and 2.8 to 42.4 months, respectively. Best response on PARPi therapy included 2 partial responses.
Conclusion
This is the first case series to describe PARPi treatment in IDH1 mutated iCCA. Results underscore the limitation of PARPi monotherapy, potentially support combined PARPi therapies, and highlight a need for effective treatment options for patients with IDH1 mutated iCCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States.
- Department of Pathology, University of Michigan, Ann Arbor, MI, United States.
ORCID-Profile: Arathi Mohan
Förderung
- NCI NIH HHS
- Rogel Cancer Center, University of Michigan
Zitieren
APA
Mohan, A., Quingalahua, E., Gunchick, V., Paul, S., Kumar-Sinha, C., Crysler, O., Zalupski, M. M., & Sahai, V. (2024). PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae163
Vancouver
Mohan A, Quingalahua E, Gunchick V, Paul S, Kumar-Sinha C, Crysler O, et al. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. The Oncologist. 2024. doi:10.1093/oncolo/oyae163
BibTeX
@article{Mohan2024,
author = {Mohan, Arathi and Quingalahua, Elit and Gunchick, Valerie and Paul, Simi and Kumar-Sinha, Chandan and Crysler, Oxana and Zalupski, Mark M and Sahai, Vaibhav},
title = {PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae163}
}
EUVIMED